The Core Technology: Perivascular Fat Attenuation Indexing (FAI)

The foundational technology of Caristo Diagnostics revolves around the discovery that coronary artery inflammation affects the surrounding adipose tissue (fat). In the presence of vascular inflammation, the composition of perivascular fat changesâ??specifically, water content increases and lipid droplet size decreases.

Caristoâ??s proprietary technology, known as the Fat Attenuation Index (FAI), utilizes advanced algorithms to analyze these subtle changes in fat attenuation on standard CCTA scans. This process allows clinicians to visualize and quantify coronary inflammation for the first time in a clinical setting. This is a paradigm shift in cardiology, as traditional diagnostics focus on "stenosis" (the narrowing of the artery), whereas Caristoâ??s technology focuses on the "activity" of the disease and the likelihood of future plaque rupture.

Flagship Product: CaRi-Heart

The primary commercial offering from Caristo Diagnostics is the CaRi-Heart platform. This is a medical device software-as-a-service (SaaS) solution designed to integrate into existing clinical workflows for hospitals and imaging centers.

1. CaRi-Heart Analysis and Reporting

The CaRi-Heart platform takes DICOM images from a standard CCTA and applies AI-driven analysis to produce a detailed report. The service provides several critical metrics: * FAI-Score: A measurement of coronary inflammation across the major coronary arteries (LAD, LCx, and RCA). This score indicates whether the inflammation is within a normal range or significantly elevated. * CaRi-Heart Risk Score: This is a validated prognostic score that combines the FAI-Score with other clinical risk factors and plaque burden metrics. It provides a percentage-based risk of a fatal cardiac event over the next eight years. * Vascular Mapping: The software provides a color-coded visualization of the coronary arteries, highlighting areas of high inflammation (represented by red/warm colors) versus stable areas (blue/cool colors).

2. Clinical Integration Services

Caristo Diagnostics offers integration services that allow their cloud-based platform to communicate with Hospital Information Systems (HIS) and Picture Archiving and Communication Systems (PACS). This ensures that radiologists and cardiologists can request an analysis and receive the resulting report within their native digital environment, facilitating faster clinical decision-making.

Clinical Utility and Patient Management

The services provided by Caristo Diagnostics address a significant gap in the "Prevention" segment of cardiovascular medicine. The companyâ??s products are used to: * Identify "At-Risk" Patients: Many patients who present with chest pain have "normal" CCTA results because they do not have significant arterial narrowing. However, these patients may still have high levels of inflammation that lead to sudden heart attacks. CaRi-Heart identifies these high-risk individuals. * Optimize Statin and Anti-inflammatory Therapy: By quantifying inflammation, physicians can more accurately prescribe preventative medications and monitor their effectiveness over time. * Refine Risk Stratification: The service moves beyond traditional risk calculators (like the Framingham Risk Score) by providing biological data specific to the patientâ??s own coronary anatomy.

Evidence Base and Regulatory Status

The validity of Caristoâ??s services is rooted in the ORFAN (Oxford Risk Factors And Non-invasive imaging) study, which involved thousands of patients and demonstrated that the FAI technology can predict heart attacks years in advance.

From a regulatory perspective, Caristo Diagnostics has achieved: * CE Mark: The CaRi-Heart platform is cleared for clinical use in Europe. * UKCA Mark: The platform is cleared for use within the United Kingdom. * FDA Status: The company has been active in seeking 510(k) clearances and has established research partnerships within the United States to facilitate clinical adoption.

Market Positioning and Strategic Value

Caristo Diagnostics occupies a niche within the MedTech market known as "Computed Tomography-derived Biomarkers." Unlike companies that focus solely on FFR-CT (Fractional Flow Reserve derived from CT) to measure blood flow, Caristo focuses on the underlying biology of the vessel wall.

The strategic value of the company lies in its ability to add a new layer of diagnostic data to an existing, widely-used imaging modality (CCTA) without requiring the patient to undergo additional radiation or the hospital to purchase new hardware. This "software-only" approach to advanced diagnostics makes it highly scalable across global healthcare systems.

Operational Reach

While rooted in the UK biotech ecosystem of Oxford, Caristo Diagnostics has expanded its reach through partnerships with global imaging companies and private healthcare providers. Their service model is primarily B2B, targeting: * Tertiary Care Hospitals: Large centers with high-volume cardiac imaging departments. * Private Diagnostic Networks: Providers looking to offer "premium" cardiovascular screenings for preventative health. * Pharmaceutical Research: Collaborating with drug developers to use FAI as a surrogate endpoint in clinical trials for new anti-inflammatory cardiovascular drugs.